Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Streicher

Showing results (1-10 of 73) with videos related to

Pageof 8
Sort By:
JNCI Cancer Spectrum|February 8, 2021
MHC and the Power of <i>P</i>Howard Streicher
Expert Review of Vaccines|December 21, 2004
Cancer vaccines: is there a future?Howard Streicher
Blood|July 15, 2017
Checking up on checkpoint inhibitorsRichard F Little, Howard Streicher
Chinese Journal of Cancer|September 6, 2014
Immune checkpoint inhibitors in clinical trialsElad Sharon, Howard Streicher, Priscila Goncalves, et al.
Oncology (Williston Park, N.Y.)|February 26, 2003
Clinical Trials Referral Resource. Clinical trials in cervical cancerEdward L Trimble, Mason Schoenfeldt, Howard Streicher, et al.
Journal of the National Cancer Institute|November 20, 2024
First cycle toxicity and survival in patients with rare cancers treated with checkpoint inhibitorsMegan Othus, Sandip P Patel, Young Kwang Chae, et al.
Journal for Immunotherapy of Cancer|July 6, 2021
Ocular adverse events in PD-1 and PD-L1 inhibitorsLeAnne Young, Shanda Finnigan, Howard Streicher, et al.
Journal of the National Cancer Institute|January 20, 2024
Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trialMegan Othus, Sandip P Patel, Young K Chae, et al.
Gynecologic Oncology|June 26, 2007
Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia IIIMark H Einstein, Anna S Kadish, Robert D Burk, et al.
JAMA Network Open|December 1, 2020
Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti-PD1/PDL1 Clinical TrialsJoshua E Reuss, Diana Stern, Jared C Foster, et al.
Pageof 8

Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
JNCI Cancer Spectrum|February 8, 2021
MHC and the Power of <i>P</i>Howard Streicher
Expert Review of Vaccines|December 21, 2004
Cancer vaccines: is there a future?Howard Streicher
Blood|July 15, 2017
Checking up on checkpoint inhibitorsRichard F Little, Howard Streicher
Chinese Journal of Cancer|September 6, 2014
Immune checkpoint inhibitors in clinical trialsElad Sharon, Howard Streicher, Priscila Goncalves, et al.
Oncology (Williston Park, N.Y.)|February 26, 2003
Clinical Trials Referral Resource. Clinical trials in cervical cancerEdward L Trimble, Mason Schoenfeldt, Howard Streicher, et al.
Journal of the National Cancer Institute|November 20, 2024
First cycle toxicity and survival in patients with rare cancers treated with checkpoint inhibitorsMegan Othus, Sandip P Patel, Young Kwang Chae, et al.
Journal for Immunotherapy of Cancer|July 6, 2021
Ocular adverse events in PD-1 and PD-L1 inhibitorsLeAnne Young, Shanda Finnigan, Howard Streicher, et al.
Journal of the National Cancer Institute|January 20, 2024
Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trialMegan Othus, Sandip P Patel, Young K Chae, et al.
Gynecologic Oncology|June 26, 2007
Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia IIIMark H Einstein, Anna S Kadish, Robert D Burk, et al.
JAMA Network Open|December 1, 2020
Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti-PD1/PDL1 Clinical TrialsJoshua E Reuss, Diana Stern, Jared C Foster, et al.
Pageof 8